9 SEPTEMBER - OCTOBER 2025CANADAwho undergo cervical cancer screening and decrease the number of future cases of late-stage cervical cancer. TIMELINE + SAMPLE SIZE-Working with a limited amount of time during which to complete the pilot, the Rosy team completed the design and engineering efforts module in two weeks and were able to continue to iterate the format in real time. They then collected data for the following nine weeks from May 26, 2022 until July 31st, 2022. In that time, 4,003 women on the Rosy platform, ranging from ages 17-84, completed the intervention.METHOD-The in-app module on the Rosy platform began with a pre-test to assess the women's baseline understanding of HPV, risk factors for cervical cancer, and the overall intention to discuss screening with their medical providers. Users then completed a series of educational screens in keeping with Rosy's typical in-app format that provided information on cervical cancer incidence, HPV and its relationship to cervical cancer, HPV transmission, risk factors for development of cervical cancer, and instructions on risk reduction. Lastly, the intervention included a post-test to assess the difference before and after the intervention. PILOT OUTCOMES-At the conclusion of data collection, we observed the following outcomes-The Rosy module increased understanding of HPV and cervical cancer by an average of 62 percent across all age groups. The Rosy module increased intent to discuss screening with providers by an average of 45 percent in all age groups, moving more than 800 women into a higher level of intention to discuss screening with their provider.Jill Downey, Disease Area Marketing Manager (Cervical Cancer) at Roche Tissue Diagnostics commented: The Roche team was extremely impressed with Rosy and their objective. As a clinician, Dr. Harper saw an unmet need within her patient population and built an approachable and engaging platform around that need.Through this partnership, we wanted to see if users would be willing to engage with content surrounding cervical cancer screening. We were very pleased with the overall engagement, specifically the intent to get screened as a result of engaging with the content.SUMMARY & FUTURE APPLICATIONS-Rosy's intervention was able to significantly increase women's understanding of HPV and cervical cancer screening and prevention, as well as their intention to discuss appropriate screening strategies with their providers.We are now a proven partner able to connect healthcare partners with their consumers and create positive change in educational and healthcare behavior outcomes while offering extensive value to the healthcare consumer. With continued scale, these opportunities have the ability to change not only the health of individuals but the health of larger populations as well. Additional opportunities for partnership include personalized educational interventions in other important and underserved areas of health, novel research and data analysis, expanded healthcare consumer targeting specific to objectives, development of follow-up measures including reminders to schedule and discuss healthcare interventions, development of after-care reporting, and more. ROSY OFFERS PERSONALIZED AND HOLISTIC SOLUTIONS FOR SEXUAL WELLNESS. OUR RESEARCH-BACKED OFFERINGS SPAN A WOMAN'S ENTIRE LIFESPAN, FROM MENSTRUATION THROUGH MENOPAUSE AND BEYOND
< Page 8 | Page 10 >